These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 16134757

  • 1. [Enfuvirtide, mechanism of action and pharmacological properties].
    Kapić E, Becić F, Zvizdić S.
    Med Arh; 2005; 59(5):313-6. PubMed ID: 16134757
    [Abstract] [Full Text] [Related]

  • 2. Enfuvirtide.
    Lalezari JP, Luber AD.
    Drugs Today (Barc); 2004 Mar; 40(3):259-69. PubMed ID: 15148534
    [Abstract] [Full Text] [Related]

  • 3. Drug profile: enfuvirtide (Fuzeon, ENF, T-20).
    Pham PA.
    Hopkins HIV Rep; 2003 May; 15(3):1-2. PubMed ID: 12809104
    [No Abstract] [Full Text] [Related]

  • 4. Enfuvirtide (T-20): potentials and challenges.
    Foy K, Juethner SN.
    J Assoc Nurses AIDS Care; 2004 May; 15(6):65-71. PubMed ID: 15538017
    [Abstract] [Full Text] [Related]

  • 5. Enfuvirtide: first fusion inhibitor for treatment of HIV infection.
    Jamjian MC, McNicholl IR.
    Am J Health Syst Pharm; 2004 Jun 15; 61(12):1242-7. PubMed ID: 15259753
    [Abstract] [Full Text] [Related]

  • 6. [Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1].
    Raffi F.
    Med Mal Infect; 2004 Sep 15; 34 Spec No 1():8-17. PubMed ID: 15742550
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Resistance to enfuvirtide, the first HIV fusion inhibitor.
    Greenberg ML, Cammack N.
    J Antimicrob Chemother; 2004 Aug 15; 54(2):333-40. PubMed ID: 15231762
    [Abstract] [Full Text] [Related]

  • 11. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.
    Fung HB, Guo Y.
    Clin Ther; 2004 Mar 15; 26(3):352-78. PubMed ID: 15110129
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Enfuvirtide and cutaneous injection-site reactions.
    Mirza RA, Turiansky GW.
    J Drugs Dermatol; 2012 Oct 15; 11(10):e35-8. PubMed ID: 23134996
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Enfuvirtide: the first step for a new strategy of antiretroviral therapy].
    Bottaro EG.
    Medicina (B Aires); 2007 Oct 15; 67(2):195-205. PubMed ID: 17593608
    [Abstract] [Full Text] [Related]

  • 16. Enfuvirtide for prophylaxis against HIV Infection.
    Ferranti S, Menichetti F.
    N Engl J Med; 2003 Aug 21; 349(8):815. PubMed ID: 12930939
    [No Abstract] [Full Text] [Related]

  • 17. Development of HIV fusion inhibitors.
    Schneider SE, Bray BL, Mader CJ, Friedrich PE, Anderson MW, Taylor TS, Boshernitzan N, Niemi TE, Fulcher BC, Whight SR, White JM, Greene RJ, Stoltenberg LE, Lichty M.
    J Pept Sci; 2005 Nov 21; 11(11):744-53. PubMed ID: 16130177
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
    Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M, TORO 2 Study Group.
    N Engl J Med; 2003 May 29; 348(22):2186-95. PubMed ID: 12773645
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.